Shots:

• Accord launches Zercepac as s a biosimilar referencing Herceptin in the UK- following the EC’s approval in Jul’2020.
• The EC’s approval is based on a series of robust studies including comparative quality studies- pre/ clinical studies. The results confirmed the Zercepac’s bio-similarity- demonstrating comparable efficacy and safety to the Herceptin
• Zercepac is the first mAb and the fourth biosimilar launched in the EU and is indicated for patients with HER2+ eBC- HER2+ mBC and previously untreated HER2+ metastatic gastric cancer and will be available in a 150mg single-dose vial

­ Ref: PRNewswire | Image: Suffolk